Introduction: The MET gene and its pathway normally plays a crucial role in cell
homeostasis, motility, and apoptosis. However, when the MET gene is altered, there is an …

MET proto-oncogene (MET) alterations are known driver oncogenes in non-small cell lung
cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive …

Simple Summary Around 3% of patients with Non-Small-Cell Lung Cancer (NSCLC)
harbour a MET exon 14 skipping mutation (METex14). Early mutation identification is …

The tyrosine kinase receptor mesenchymal epithelial transition (MET) is a proto-oncogene
that, through the activation of the MET-hepatocyte growth factor (HGF) pathway, encodes a …

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …

Targeting c-MET in the battle against advanced nonsmall-cell... : Current Opinion in
Oncology Targeting c-MET in the battle against advanced nonsmall-cell lung cancer …

Simple Summary MET is a receptor tyrosine kinase encoded by the MET proto-oncogene
that has a significant role in cancer cell progression. Several drugs targeting MET are under …

The c-MET proto-oncogene (MET) plays an important role in lung oncogenesis, affecting
cancer-cell survival, growth and invasiveness. The MET receptor in non-small–cell lung …

Abstract Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved
in the last years due to development and clinical approval of highly effective agents …

In recent years, we have seen the development and approval for clinical use of an
increasing number of therapeutic agents against actionable oncogenic drivers in metastatic …